TIL therapy
Tumor infiltrating lymphocyte (TIL) therapy is our lead T-cell-based immunotherapy platform. We are currently investigating TIL therapy in clinical trials of multiple advanced solid tumors. Our initial strategy is to deliver TIL as a single-agent therapy for patients with late-stage solid tumor cancers. For earlier intervention, we are investigating the potential of our TIL therapy in combination with a class of immunotherapy drugs called immune checkpoint inhibitors, or ICIs.
These immunotherapy drugs seek to overcome one of the main escape mechanisms of cancer against an immune system attack. TIL therapy and ICIs have the potential to work synergistically to target and attack cancer cells while breaking down barriers to enable the immune system to mount a response. We are currently investigating TIL in combination with ICIs in clinical trial cohorts of patients with multiple advanced solid tumors who have not previously received ICIs.
Key steps in the TIL therapy process
A tumor sample is removed from the patient and shipped overnight to our centralized manufacturing facility, where the TIL are isolated.
The patient-specific TIL are amplified and reinvigorated using our proprietary manufacturing process, which we refer to as Gen 2 to reflect our successful efforts to streamline TIL manufacturing from several weeks to 22 days. The TIL therapy is cryopreserved and sent back for infusion into the patient.
The patient receives a preparative regimen (lymphodepleting chemotherapy) prior to TIL infusion. The treatment regimen is completed with a short course of interleukin-2 (IL-2) to promote T-cell activity.
This site may contain information on an investigational agent(s) or investigational uses of approved agent(s) that has not been reviewed or approved by the FDA or other regulatory authorities. Iovance does not endorse or recommend any unapproved use of its products. Please refer to product prescribing information, where available.